Morning, Thursday, 6th June 2019
The Caledonian Club, 9 Halkin Street, London SW1X 7DR
THIS EVENT IS CPD CERTIFIED
This conference will be a timely opportunity to discuss the future for the regulation of medicines, clinical trials and medical devices in the UK - looking at patient safety, access and next steps for policy.
Attendees will discuss what more could be done to ensure that the regulatory process supports the development of new treatments within the UK - in light of the announcement of additional investment in the Life Sciences Sector Deal 2, which set out sector and Government actions to promote innovative regulation that keeps pace with emerging technologies.
The seminar follows the publication of the NHS Long Term Plan, which set out further actions to support the UK economy and supported the Life Sciences Sector Deal.
The agenda includes discussion on the future for regulation to ensure the transparency of clinical trials and maintain public trust - following the Government’s response to the Science and Technology Commons Select Committee’s report into research integrity, which included commitments to increase transparency measures under new regulations.
Attendees will assess priorities for the Health Research Authority as it develops a new strategy for clinical trials transparency, ahead of the expected publication in December 2019 - such as if further funding will be needed, how improvements in transparency will be measured and how non-compliance with transparency regulations should be responded to.
Delegates will also discuss the changing landscape of healthcare regulation and the future role of the UK in European regulatory procedures - including key issues for maintaining access, innovation and the supply of medicines to the UK.
The seminar comes as the MHRA prepares for different post-Brexit scenarios and as the European Medicines Agency (EMA) relocates to Amsterdam.
Sessions address the impact of the Early Access to Medicine Scheme, which aims to give patients access to medicines that do not yet have marketing authorisation - as well as next steps for working with patients in the decision making process.
Further sessions look at what more could be done to deter the manufacture and supply of fake products in the future and also educate the public on safety advice when purchasing medicines, following the seizures of more than £2m of fake medicines and devices by the MHRA.